Treatment of end-of-dose wearing-off in Parkinson's disease: Stalevo® (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess®/Comtan® (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

DOI

  • D. J. Brooks
  • Y. Agid, Pitie-Salpetriere Hospital
  • ,
  • K. Eggert, Philipps-Universität Marburg
  • ,
  • H. Widner, Lund University Hospital
  • ,
  • K. Østergaard, Aarhus Kommunehospital
  • ,
  • A. Holopainen, Orion Pharma

The aim of this study was to evaluate the efficacy of the new optimised levodopa, Stalevo® (levodopa, carbidopa and entacapone) in patients with Parkinson's disease experiencing end-of-dose wearing-off. Treatment with Stalevo was compared to treatment with traditional immediate-release levodopa and dopa-decarboxylase inhibitor (DDCI) formulations along with adjunct entacapone (Comtess®/Comtan®). A European, open, parallel-group, active treatment-controlled phase IIIb study evaluating 176 patients randomised to switch from their current regimen of levodopa/DDCI to either an equivalent dose of Stalevo or levodopa/DDCI plus entacapone. After 6 weeks, treatments were assessed using the Clinical Global Impression of Change, the Unified Parkinson's Disease Rating Scale and a Motor Fluctuations Questionnaire. Over 70% of patients in both the Stalevo and adjunct entacapone arms felt that they were clinically improved and over 80% experienced a reduction in fluctuations. Although there was no significant difference between Stalevo and levodopa/DDCI plus entacapone with regard to motor improvement and side effects, 81% of patients stated that they preferred treatment with Stalevo compared with taking two separate tablets (i.e. levodopa/DDCI and entacapone). Stalevo was well tolerated and safe when substituted for levodopa DDCI preparations.

Original languageEnglish
JournalEuropean Neurology
Volume53
Issue4
Pages (from-to)197-202
Number of pages6
ISSN0014-3022
DOIs
Publication statusPublished - 1 Jul 2005

    Research areas

  • Catechol-O-methyltransferase inhibition, Dopadecarboxylase inhibitor, Levodopa, Parkinson's disease, Stalevo®, Wearing-off

See relations at Aarhus University Citationformats

ID: 131250807